Zhiwei Wang

Summary

Country: China

Publications

  1. Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang Z, et al. Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta. 2015;1855:50-60 pubmed publisher
  2. Zhang Y, Sun M, Shi W, Yang Q, Chen C, Wang Z, et al. Arsenic trioxide suppresses transcription of hTERT through down-regulation of multiple transcription factors in HL-60 leukemia cells. Toxicol Lett. 2015;232:481-9 pubmed publisher
    ..Notably, we observed that down-regulation of these four factors by their siRNAs potentiates ATO-induced cell growth inhibition and apoptosis. Therefore, our results provide a novel mechanism of action of ATO for the treatment of APL. ..
  3. Wang L, Zhang J, Wan L, Zhou X, Wang Z, Wei W. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther. 2015;151:141-51 pubmed publisher
    ..Taken together, development of specific Cdc20 inhibitors could be a novel strategy for the treatment of human cancers with elevated Cdc20 expression. ..
  4. Zheng N, Wang Z, Wei W. Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins. Int J Biochem Cell Biol. 2016;73:99-110 pubmed publisher
    ..We conclude that inhibitors of F-box proteins could have promising therapeutic potentials in part through controlling of aberrant cell cycle progression for cancer therapies. ..
  5. Zheng N, Zhou Q, Wang Z, Wei W. Recent advances in SCF ubiquitin ligase complex: Clinical implications. Biochim Biophys Acta. 2016;1866:12-22 pubmed publisher
    ..Lastly, we suggest that targeting F-box proteins could possibly open new avenues for the treatment and prevention of human cancers. ..